Clinical trials: GI Disorders
Esophageal Cancer, Gastric Cancer
DX-8951f in Treating Patients With Metastatic Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have…
- Trial name
- NCT00017212
- Testing
- exatecan mesylate
- Where
- 6 sites in United States, Canada
- Sponsor
- Daiichi Sankyo
Peptic Ulcer Hemorrhage
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients.
- Trial name
- NCT00037570
- Testing
- Pantoprazole
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Triple Negative Breast Cancer (TNBC), Colorectal Cancer
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
This is a Phase 1a/1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific…
- Conditions
- Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer
- Trial name
- CT-202 (NCT07545122)
- Testing
- CT-202
- Where
- 6 sites in Australia
- Volunteers
- 162 people
- Sponsor
- Context Therapeutics Inc.
Advanced Solid Tumours, Carcinoma Non-small Cell Lung
First in Human Study of AZD9592 in Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary…
- Conditions
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
- Trial name
- EGRET (NCT05647122)
- Testing
- AZD9592, Osimertinib, 5-Fluorouracil (5-FU)
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Gastroparesis
Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis
Gastroparesis, also referred to as delayed gastric emptying, is a debilitating, chronic disorder that slows or stops the passage of food from the stomach to the small intestine.
- Trial name
- NCT02187094
- Testing
- TC-6499
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Targacept Inc.
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Gastroenteritis, Gastritis
BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (BEKINDA) (Ondansetron 24 mg Bimodal Release Tablets) for Acute Gastroenteritis.
- Trial name
- GUARD (NCT02246439)
- Testing
- RHB-102
- Where
- 26 sites in United States
- Volunteers
- 330 people
- Sponsor
- RedHill Biopharma Limited
Ulcerative Colitis
SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101
A randomized, double-blind placebo-controlled first in human study in approximately 36 male healthy subjects and approximately 20 male and female patients with active UC who have had an inadequate response to or demonstrated…
- Trial name
- AURIGA1 (NCT04224857)
- Testing
- AMT-101
- Where
- 4 sites in Georgia, Germany and 2 more
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Applied Molecular Transport
Untreated, Unresectable, or Metastatic Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or…
- Trial name
- NCT07221357
- Testing
- Pumitamig, FOLFOX, FOLFIRI
- Where
- 286 sites in United States, Argentina and 23 more
- Volunteers
- 990 people
- Sponsor
- Bristol-Myers Squibb
Niemann-Pick Disease, Type C
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
Due to different study designs, the sponsor separated Part C into this separate registration (NCT04958642), leaving Parts A/B in NCT02534844.
- Trial name
- NCT04958642
- Testing
- Adrabetadex
- Where
- 30 sites in United States, Australia and 7 more
- Volunteers
- 66 people
- Sponsor
- Mandos LLC
Advanced or Recurrent Colorectal Cancer
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be studied. Specifically, information will be collected on the following as events of interest: skin disorders, interstitial lung disease…
- Trial name
- NCT02089737
- Testing
- Panitumumab
- Volunteers
- 3,091 people
- Sponsor
- Takeda
Colorectal Cancer
A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)
This is a randomized, double-blind, parallel group, placebo-controlled study evaluate the preliminary efficacy and safety of MB-6 (320 mg/capsule, 6 capsules tid) versus placebo in addition to standard chemotherapy in the…
- Trial name
- NCT01047475
- Testing
- MB-6
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- Microbio Co Ltd
Esophageal Cancer
Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer
The primary purpose of this study is to assess the safety and feasibility of giving TNFerade™ with 5-FU, Cisplatin and radiation therapy to patients with locally advanced, esophageal cancer prior to surgical resection.
- Trial name
- NCT00051480
- Testing
- TNFerade
- Where
- 12 sites in United States
- Sponsor
- GenVec
Gastrointestinal Disorder, Immunologic Diseases in Children
Whole Grain, Gluten-containing Cereal and PROBIOtics to Evaluate Digestive TOLERAance and Immuno-inflammatory Response
This study will assess the development of gastrointestinal health in terms of digestive tolerability and immune-inflammatory response at the intestinal level comparing a conventional gluten-free cereal with a new cereal with…
- Trial name
- PROBIOTOLERA (NCT04021303)
- Testing
- Experimental cereal, Conventional cereal
- Where
- Spain
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Laboratorios Ordesa
Neoplasms, Colorectal
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
Subjects will be entered into cohorts of 3 for the dose escalation phase so that the maximum tolerated dose can be determined. 18 additional patients will be recruited once the maximum tolerated dose (MTD) is determined for…
- Trial name
- NCT00540943
- Testing
- Pazopanib, Cetuximab, Irinotecan
- Where
- 2 sites in France
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Colitis, Ulcerative, Recurrence
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)
This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs.
- Trial name
- NCT00746447
- Testing
- mesalamine granules
- Where
- Germany
- Volunteers
- 648 people
- Sponsor
- Dr. Falk Pharma GmbH
Ulcerative Colitis (UC)
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the…
- Trial name
- NCT03398148
- Testing
- risankizumab IV, risankizumab SC
- Where
- 430 sites in United States, Argentina and 42 more
- Volunteers
- 1,558 people
- Sponsor
- AbbVie
Colorectal Cancer, Advanced Adenocarcinoma
A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China
According to data from Global Cancer Statistics 2018, colorectal cancer (CRC) ranks second in incidence and fifth in mortality among all cancers in China.
- Conditions
- Colorectal Cancer, Advanced Adenocarcinoma, Hyperplastic Polyp, Colorectal Neoplasms
- Trial name
- NCT04722055
- Testing
- Multigene Methylation Detection Kit
- Where
- China
- Volunteers
- 1,273 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Colorectal Cancer
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection.
- Trial name
- NCT06515821
- Testing
- ONCOSCREEN
- Where
- 8 sites in Bulgaria, France and 4 more
- Volunteers
- 4,100 people
- Sponsor
- Firalis SA
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.